The first amylin analog — native amylin with its self-aggregation edited out. Structurally it is Amylin analog (synthetic 37 aa peptide).

How strong is the evidence for Pramlintide?

PeptideHormone grades Pramlintide at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.

What is the half-life of Pramlintide?

The reported circulating half-life of Pramlintide is ~48 min.

Is Pramlintide the same as Symlin?

Symlin is a brand name of Pramlintide — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.

Pramlintide

The first amylin analog — native amylin with its self-aggregation edited out.

Also known as Symlin.

AnalogEstablishedBased on AmylinCompare with IAPP Compare lineage

What disqualifies a hormone as a drug is often a single residue. Correct it, and a molecule the body already makes becomes prescribable.

Identity

Class: Amylin analog (synthetic 37 aa peptide)
Source: Synthetic analog of human amylin
Receptor: Amylin receptors (calcitonin receptor + RAMP)

Key properties

Evidence floorClinicalREF1CLIN1

Molecular weight

~3,949.4 Da

REF

Half-life (native)

~48 min

CLIN

Model dosing

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Pramlintide is a synthetic amylin analog carrying three proline substitutions — borrowed from non-aggregating rodent amylin — that prevent the fibril formation which makes native human amylin undruggable. At amylin receptors it reproduces amylin's biology: slowing gastric emptying, suppressing post-meal glucagon, and promoting satiety. It is approved as an adjunct to mealtime insulin, the two hormones' natural partnership rebuilt as a drug.

Same hormone, three edits. Native amylin tangles into fibrils and dies in the vial; three prolines, borrowed from the rat, straighten it into the first amylin drug — the proof of concept the whole amylin renaissance is built on.

In depth

Insulin has a co-pilot almost nobody has heard of. Every time the beta cell releases insulin, it releases amylin in the same granules — a second hormone that handles the jobs insulin can't: slowing the meal's arrival, silencing glucagon after eating, and telling the brain the meal is over. In type 1 diabetes both are lost at once, yet for a century only one was replaced. Pramlintide is the attempt to replace the other — the first, and still the only, amylin drug.

The engineering problem was vicious. Native human amylin clumps into fibrils — the same tendency that deposits it as amyloid in the diabetic pancreas — making it impossible to formulate. The fix was borrowed from rodents, whose amylin never aggregates: three proline substitutions at the fibril-forming positions broke the clumping while keeping the receptor pharmacology. Symlin, a mealtime injection beside insulin, reached approval in 2005. The fibril edited out, the co-pilot restored.

Commercially it was a quiet drug — a separate injection at every meal, for a benefit measured in smoother glucose curves rather than dramatic numbers. But pramlintide is the proof of concept the amylin renaissance is built on. Cagrilintide took the same axis and stretched it from 48 minutes to a week; amycretin folded it into a single molecule with GLP-1. The forgotten twin's drug came first, and everything the amylin field is now betting started with three prolines.

Reference notes

The proline substitutions solve amylin's self-aggregation problem — the core engineering that made a stable amylin drug possible.
Approved as an adjunct to mealtime insulin in type 1 and type 2 diabetes.
Complements insulin rather than replacing it — amylin and insulin are co-secreted natively.

Common questions

What is Pramlintide?: The first amylin analog — native amylin with its self-aggregation edited out. Structurally it is Amylin analog (synthetic 37 aa peptide).
How does Pramlintide work?: Pramlintide is a synthetic amylin analog carrying three proline substitutions — borrowed from non-aggregating rodent amylin — that prevent the fibril formation which makes native human amylin undruggable. At amylin receptors it reproduces amylin's biology: slowing gastric emptying, suppressing post-meal glucagon, and promoting satiety. It is approved as an adjunct to mealtime insulin, the two hormones' natural partnership rebuilt as a drug.
How strong is the evidence for Pramlintide?: PeptideHormone grades Pramlintide at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of Pramlintide?: The reported circulating half-life of Pramlintide is ~48 min.
Is Pramlintide the same as Symlin?: Symlin is a brand name of Pramlintide — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

1.Pramlintide and the treatment of diabetes: a review of the data since its introduction · Expert opinion on pharmacotherapy, 2011 · PMID 21564002
2.Pramlintide · , 2006 · PMID 30000033

External references

Pramlintide in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.